Clinical Trial

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2020-11-30; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2021-04-20
Trial Details
NCT Number NCT04655404
Lead Sponsor Nationwide Children's Hospital
Conditions High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Enrollment 15 participants
Start Date 2021-04-08
Primary Completion 2026-12-01 (estimated)
Study Completion 2036-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-18